SG11201505493QA - Heteroaromatic compounds as pi3 kinase modulators - Google Patents
Heteroaromatic compounds as pi3 kinase modulatorsInfo
- Publication number
- SG11201505493QA SG11201505493QA SG11201505493QA SG11201505493QA SG11201505493QA SG 11201505493Q A SG11201505493Q A SG 11201505493QA SG 11201505493Q A SG11201505493Q A SG 11201505493QA SG 11201505493Q A SG11201505493Q A SG 11201505493QA SG 11201505493Q A SG11201505493Q A SG 11201505493QA
- Authority
- SG
- Singapore
- Prior art keywords
- heteroaromatic compounds
- kinase modulators
- modulators
- kinase
- heteroaromatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767721P | 2013-02-21 | 2013-02-21 | |
| PCT/US2014/016643 WO2014130375A1 (en) | 2013-02-21 | 2014-02-15 | Heteroaromatic compounds as pi3 kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505493QA true SG11201505493QA (en) | 2015-08-28 |
Family
ID=51351332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505493QA SG11201505493QA (en) | 2013-02-21 | 2014-02-15 | Heteroaromatic compounds as pi3 kinase modulators |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9573953B2 (en) |
| EP (1) | EP2958564B1 (en) |
| JP (1) | JP6389829B2 (en) |
| KR (1) | KR102148681B1 (en) |
| AU (1) | AU2014219256B2 (en) |
| BR (1) | BR112015018318A2 (en) |
| CA (1) | CA2898294C (en) |
| ES (1) | ES2674705T3 (en) |
| HK (1) | HK1218385A1 (en) |
| MX (1) | MX2015010700A (en) |
| MY (1) | MY182036A (en) |
| RU (1) | RU2672910C9 (en) |
| SG (1) | SG11201505493QA (en) |
| TW (1) | TWI620749B (en) |
| WO (1) | WO2014130375A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6877407B2 (en) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Compounds and compositions useful for the treatment of NTRK-related disorders |
| SG10201912607SA (en) * | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| WO2018136202A2 (en) * | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| ES2928773T3 (en) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Protein kinase inhibitors to promote liver regeneration or reduce or prevent hepatocyte death |
| WO2018169700A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| CN109867671B (en) * | 2017-12-02 | 2020-07-07 | 广东东阳光药业有限公司 | Crystal form of pyrazolo [1,5-a ] pyridine compound, and pharmaceutical composition and application thereof |
| CN109867668B (en) * | 2017-12-02 | 2021-03-26 | 广东东阳光药业有限公司 | Crystal form of pyrazolo [1,5-a ] pyridine compound, and pharmaceutical composition and application thereof |
| CN109867669B (en) * | 2017-12-02 | 2021-02-26 | 广东东阳光药业有限公司 | Crystal form of pyrazolo [1,5-a ] pyridine compound, and pharmaceutical composition and application thereof |
| CN109867672B (en) * | 2017-12-02 | 2020-07-07 | 广东东阳光药业有限公司 | Salts of pyrazolo [1,5-a ] pyridine derivative and use thereof |
| CN109867670B (en) * | 2017-12-02 | 2020-07-07 | 广东东阳光药业有限公司 | Monosodium salt of pyrazolo [1,5-a ] pyridine compound and medical application thereof |
| EP3727379A4 (en) * | 2017-12-20 | 2021-12-15 | Sunshine Lake Pharma Co., Ltd. | Salts of pyrazolo[1,5-a]pyridine derivative and use thereof |
| CN112770757B (en) * | 2018-10-19 | 2024-01-16 | 广东东阳光药业股份有限公司 | Pharmaceutical composition or pharmaceutical composition for treating fibrosis diseases |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| JPH09506253A (en) | 1993-11-30 | 1997-06-24 | マクギル・ユニヴァーシティ | Inhibition of DNA methyltransferase |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6268137B1 (en) | 1996-05-22 | 2001-07-31 | Methylgene, Inc. | Specific inhibitors of DNA methyl transferase |
| US6020318A (en) | 1997-05-30 | 2000-02-01 | Methylgene, Inc. | DNA methyltransferase genomic sequences and antisense oligonucleotides |
| JP2002512508A (en) | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | DNA methyltransferase genomic sequence and antisense oligonucleotide |
| US6066625A (en) | 1998-02-03 | 2000-05-23 | Methylgene, Inc. | Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences |
| US6953783B1 (en) | 1998-10-19 | 2005-10-11 | Methylgene, Inc. | Modulation of gene expression by combination therapy |
| EP1173562A2 (en) | 1999-05-03 | 2002-01-23 | Methylgene, Inc. | Inhibition of histone deacetylase |
| KR20020070285A (en) | 1999-11-23 | 2002-09-05 | 메틸진, 인크. | Inhibitors of histone deacetylase |
| EP2093292A2 (en) | 2000-03-24 | 2009-08-26 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
| JP2003528074A (en) | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | Histone deacetylase inhibitor |
| JP4206273B2 (en) * | 2001-04-27 | 2009-01-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pyrazolo [1,5-a] pyridine compounds and pharmaceuticals thereof |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| JP3795044B2 (en) | 2001-09-14 | 2006-07-12 | メシルジーン、インコーポレイテッド | Inhibitors of histone deacetylase |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CA2501265A1 (en) | 2002-10-17 | 2004-04-29 | Methylgene Inc. | Inhibitors of histone deacetylase |
| AU2003299651A1 (en) * | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| ES2222813B1 (en) * | 2003-07-24 | 2005-12-16 | Ferrer Internacional, S.A. | N- (3- (3-SUBSTITUTES-PIRAZOLO (1,5-A) PIRIMIDIN-7-IL) -PENYL) -SULPHONAMIDS AND RELATED COMPOSITIONS AND METHODS |
| EP1663953A1 (en) | 2003-09-24 | 2006-06-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| KR101258504B1 (en) | 2004-03-26 | 2013-04-26 | 메틸진 인코포레이티드 | Inhibitors of histone deacetylase |
| EP1781664B1 (en) | 2004-07-30 | 2013-09-04 | MethylGene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| CA2602444C (en) | 2005-03-23 | 2013-03-19 | F.Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists |
| JP2011500823A (en) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pyridosulfonamide derivatives as PI3 kinase inhibitors |
| WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
| US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| PT2467141T (en) | 2009-08-17 | 2019-02-06 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| EP2608669B1 (en) * | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| CN102675286B (en) | 2011-03-07 | 2015-08-19 | 中国科学院上海药物研究所 | One class indazole compounds and preparation method thereof, purposes and pharmaceutical composition |
| CN103748099B (en) | 2011-05-19 | 2016-08-17 | 卡洛斯三世国家癌症研究中心基金会 | Macrocyclic compound as kinases inhibitor |
| WO2012174312A2 (en) | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
| KR101274986B1 (en) | 2011-07-27 | 2013-06-17 | 한국과학기술원 | Imidazopyridine derivatives, PI3K and/or mTOR inhibiting composition and composition used in diseases linked to PI3K and/or mTOR comprising the same |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| CN102924450A (en) | 2012-11-01 | 2013-02-13 | 西安交通大学 | 6-(5-pyridyl)-1,2,4-triazolopyridine compound, and preparation method and application thereof |
-
2014
- 2014-02-15 MX MX2015010700A patent/MX2015010700A/en unknown
- 2014-02-15 RU RU2015131467A patent/RU2672910C9/en active
- 2014-02-15 SG SG11201505493QA patent/SG11201505493QA/en unknown
- 2014-02-15 KR KR1020157019069A patent/KR102148681B1/en active IP Right Grant
- 2014-02-15 MY MYPI2015702491A patent/MY182036A/en unknown
- 2014-02-15 WO PCT/US2014/016643 patent/WO2014130375A1/en active Application Filing
- 2014-02-15 JP JP2015558892A patent/JP6389829B2/en active Active
- 2014-02-15 EP EP14754663.4A patent/EP2958564B1/en active Active
- 2014-02-15 BR BR112015018318A patent/BR112015018318A2/en not_active Application Discontinuation
- 2014-02-15 US US14/181,670 patent/US9573953B2/en active Active
- 2014-02-15 CA CA2898294A patent/CA2898294C/en active Active
- 2014-02-15 ES ES14754663.4T patent/ES2674705T3/en active Active
- 2014-02-15 AU AU2014219256A patent/AU2014219256B2/en active Active
- 2014-02-18 TW TW103105349A patent/TWI620749B/en active
-
2016
- 2016-06-03 HK HK16106363.8A patent/HK1218385A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2898294C (en) | 2020-06-09 |
| US20140234254A1 (en) | 2014-08-21 |
| AU2014219256A1 (en) | 2015-07-30 |
| KR102148681B1 (en) | 2020-08-27 |
| HK1218385A1 (en) | 2017-02-17 |
| BR112015018318A2 (en) | 2017-08-22 |
| MY182036A (en) | 2021-01-18 |
| TW201443049A (en) | 2014-11-16 |
| US9573953B2 (en) | 2017-02-21 |
| RU2015131467A (en) | 2017-03-24 |
| AU2014219256B2 (en) | 2017-02-16 |
| EP2958564B1 (en) | 2018-05-09 |
| WO2014130375A1 (en) | 2014-08-28 |
| EP2958564A1 (en) | 2015-12-30 |
| JP2016509056A (en) | 2016-03-24 |
| EP2958564A4 (en) | 2016-10-26 |
| KR20150118102A (en) | 2015-10-21 |
| RU2672910C9 (en) | 2019-06-04 |
| RU2672910C2 (en) | 2018-11-21 |
| ES2674705T3 (en) | 2018-07-03 |
| MX2015010700A (en) | 2017-01-23 |
| JP6389829B2 (en) | 2018-09-12 |
| CA2898294A1 (en) | 2014-08-28 |
| TWI620749B (en) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218385A1 (en) | Heteroaromatic compounds as pi3 kinase modulators pi3 | |
| AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
| GB201309085D0 (en) | Compounds | |
| GB201302927D0 (en) | Compounds | |
| GB201310542D0 (en) | Compounds | |
| HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
| HK1221465A1 (en) | Novel heterocyclic compounds | |
| GB201311951D0 (en) | Compounds | |
| GB201309508D0 (en) | Compounds | |
| ZA201508864B (en) | Substituted heterocyclic compounds as crac modulators | |
| HK1212228A1 (en) | Emulsified composition for external application | |
| AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201317619D0 (en) | Compounds | |
| GB201312901D0 (en) | Compounds | |
| GB201311953D0 (en) | Compounds | |
| EP3010923A4 (en) | Pyrroloquinazoline compounds | |
| EP2948457A4 (en) | Compounds | |
| GB201318461D0 (en) | Compounds | |
| GB201316014D0 (en) | Compounds | |
| GB201310460D0 (en) | Compounds | |
| GB201306794D0 (en) | Compounds | |
| GB201313695D0 (en) | Appetite-suppressant composition | |
| GB201306013D0 (en) | compensation | |
| GB201318323D0 (en) | Compounds | |
| GB201318143D0 (en) | Compounds |